检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:姜淑凤[1]
出 处:《湖南中医杂志》2015年第6期12-13,18,共3页Hunan Journal of Traditional Chinese Medicine
基 金:河北省中医药管理局2010年度中医药类指令性科研课题(编号:2010059)
摘 要:目的:观察股动脉加压灌注疏血通注射液治疗下肢动脉硬化闭塞症的临床疗效。方法:将88例下肢动脉硬化闭塞症患者随机分为两组,治疗组54例采用疏血通注射液股动脉加压灌注治疗,对照组34例采用疏血通注射液静脉滴注治疗。20d为1个疗程,治疗1个疗程后,比较两组临床疗效及两组治疗前后踝肱指数(ABI)。结果:总有效率治疗组为96.3%,对照组为79.4%,组间比较,差异有统计学意义(P<0.05);两组治疗前ABI比较,差异无统计学意义(P>0.05),治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.05,P<0.01)。结论:股动脉加压灌注疏血通注射液治疗下肢动脉硬化闭塞症临床疗效确切,值得推广应用。Objective:To observe the clinical efficacy of femoral artery enhancing perfusion with Shuxuetong in- jection in the treatment of lower limb arteriosclerosis obliterans. Methods : A total of 88 patients with lower limb arte- riosclerosis obliterans were randomly divided into treatment group (n = 54 )and control group (n = 34). The treatment group received femoral artery enhancing perfusion with Shuxuetong injection, while the control group was given in- travenous drip of Shuxuetong injection. Each course of treatment was 20 days for both groups. The two groups were compared in terms of treatment outcomes and the ankle -brachial index(ABI) before and after treatment. Results: There was significant difference in overall response rate between the treatment group and the control group (96.3 % vs79. 4% ,P 〈0. 05 ). There was no significant difference in ABI before treatment between the two groups (P 〉 0. 05). Both groups showed significant improvement in ABI after treatment ( p 〈 0. 05 ), and there was significant difference in ABI after treatment between the two groups(P 〈 0.01 ). Conclusion:Femoral artery enhancing perfu-sion with Shuxuetong injection has good clinical efficacy in treating lower limb arteriosclerosis obliterans and holds promise for clinical application.
关 键 词:下肢动脉硬化闭塞症 股动脉加压灌注 疏血通注射液
分 类 号:R259.435[医药卫生—中西医结合]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.33